Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Olema Pharmaceuticals, Inc. · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

During the six months ended June 30, 2026, there were no material changes to our market risk disclosures reported in our Annual Report.